The process of hemodialys is the popular renal replacement therapy in most countries, worldwide. From past few decades, there has been an increasing interest in understanding the needs of hemodialysis patients. Various risk factors, such as failures, adverse reactions, and poor outcomes of older dialysis methods are setting path for higher demand for blood dialyzers, thus propelling the overall market growth over the forecast period.
Blood dialyzers, also called hemodialyzers, are mainly used for the removal of excess fluid accumulated in kidney. Excess fluid is removed by creating a pressure gradient across two compartments of dialyzer. Three primary methods commonly used to gain access to the blood during hemodialysis are: intravenous catheter, arteriovenous fistula (AV), and synthetic graft. The type of access to these methods is determined by factors such as the expected time course of a patient's renal failure and the condition of vasculature of patient.
Global blood dialyzer market size is valued at US$ 6,241.9 million in 2022 and is expected to witness a CAGR of 6.3% over the forecast period (2022 – 2030).
Figure 1. Global Blood Dialyzer Market Share (%), by Dialysis Membrane Material, 2022
Increasing use of cellulose membrane in blood dialyzer due to its compatibility is expected to drive growth of the global blood dialyzer market over the forecast period.
Increasing use of cellulose membrane in blood dialyzer due to its compatibility is expected to drive growth of the global blood dialyzer market. For instance, on January 26, 2022, National Center for Biotechnology Information published a report on Influence of Dialysis Membranes on Clinical Outcomes: From History to Innovation, which reported that The cellulose triacetate (CTA) dialysis membrane is the most biocompatible in cellulosic membranes, Cellulose membranes were enhanced through the chemical masking of the hydroxyl groups such as by their acylation with acetate groups. These modified membranes are composed of cellulose acetate, cellulose diacetate (CDA), and cellulose triacetate (CTA), which were named according to the amount of acetate groups in each of the cellulose units. The structural adjustments decreased the majority of free hydroxyl groups on the membrane surface that could bind to complement receptor C3b, the major factor that triggers the complement activation and the cause of adverse events.
|Base Year:||2021||Market Size in 2022:||US$ 6,241.9 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||6.3%||2030 Value Projection:||US$ 10,172.9 Mn|
Baxter International, Inc.,Nikkiso Co. Ltd.,B. Braun SE,CVS Health,Nipro Corporation,Diaverum Deutschland GmbH,NxStage Medical, Inc.,Fresenius Medical Care AG & Co. KGaA, DaVita Healthcare Partners, Inc.,Asahi Kasei Medical Co., Ltd,Browndove Healthcare (F) Ltd, BAIN MEDICAL EQUIPMENT(GUANGZHOU)CO.,LTD,SB-KAWASUMI LABORATORIES, INC, Medtronic,Jihua Medical Apparatus and Instruments Co., Ltd.,Allmed Medical Care Holdings Limited and JMS Medical Co., Ltd
|Restraints & Challenges:||
Figure 2. Global Blood Dialyzer Market Share (%), by Region, 2022
Increasing product launches by key market players is expected to boost the global blood dialyzer market growth over the forecast period.
Increasing product launches by key market players is expected to drive the global blood dialyzer market growth. For instance, on March 29, 2022, Nipro Medical Corporation, a healthcare manufacturing company, announced the commercial launch of SURDIAL DX Hemodialysis System in the U.S. SURDIAL DX is a hemodialysis system designed to create an optimal dialysis treatment experience for patients and clinicians. Manufactured in Japan. SURDIAL DX was developed with key input from clinicians to offer patient-focused features for optimal performance, efficiency, and ergonomics.
Global Blood Dialyzer Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals.
Whereas covid-19 had a negative impact on kidney disease management. For instance, on April 27, 2022, according to the reports published in journal of clinical medicine, which reported that in Romania, The COVID-19 pandemic inﬂuenced renal disease management, affecting fragile patients and worsening their outcomes. The number of CKD (chronic kidney disease) patients admitted to the department decreased, to minimalize their exposure and the risk of infection.
Thus COVID-19 has hindered growth of the global blood dialyzer market during the pandemic.
Global Blood Dialyzer Market: Key Developments
Global Blood Dialyzer Market: Restraints
Factors restraining the global blood dialyzer market growth include lack of trained professionals, and increase rate of bacterial infection associated with the blood dialyzer device. Also product recalls due to lack of meeting regulatory standards is one of the major factors that is expected to hamper growth of market over the forecast period.
Key players operating in the global blood dialyzer market include Baxter International, Inc.,Nikkiso Co. Ltd.,B. Braun SE,CVS Health,Nipro Corporation,Diaverum Deutschland GmbH,NxStage Medical, Inc.,Fresenius Medical Care AG & Co. KGaA, DaVita Healthcare Partners, Inc.,Asahi Kasei Medical Co., Ltd,Browndove Healthcare (F) Ltd, BAIN MEDICAL EQUIPMENT(GUANGZHOU)CO.,LTD,SB-KAWASUMI LABORATORIES, INC, Medtronic,Jihua Medical Apparatus and Instruments Co., Ltd.,Allmed Medical Care Holdings Limited, and JMS Medical Co., Ltd.
Blood dialyzer, also known as hemodialyzer or artificial kidney, is a device used to filter blood of a person who is suffering from kidney damage. Hemodialyzer accomplishes extracorporeal removal of waste products such as creatinine, urea, and free water from the blood in states of kidney failure.
Prevalence of kidney diseases is increasing globally, due to rising geriatric population, urinary disorders, and changing lifestyles. For instance in May 2018, According to United Nations, Department of Economic and Social Affairs, Population Division, 55% of the world’s population lived in urban areas, a proportion that is expected to increase to 68% by 2050, the world’s population could add another 2.5 billion people to urban areas by 2050, with close to 90% of this increase taking place in Asia and Africa, which had influenced favourably for sustained growth of the blood dialyzer market over the next decade.
Furthermore, National Kidney Foundation 2021,published a report based on 2018 data which estimated that 1 in 3 adults in the U.S. (approximately 80 million) were at risk for kidney disease. Whereas Kidney disease affects an estimated 37 million people in the U.S. (15% of the adult population; more than 1 in 7 adults). Rising geriatric population and increased prevalence of chronic kidney diseases will lead to increasing demand for blood dialyzers in the global market. For instance, according to the reports published in Centers for Disease Control and Prevention 2021 report, More than 1 in 7, that is 15% of U.S. adults or 37 million people, are estimated to have chronic kidney disease. (CKD), CKD is more common in people aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.